Takeda to Revise FY2025 Financials Following $2.5B Antitrust Verdict; FY2026 Guidance Unchanged
TAK sits 22% above its 52-week low of $12.99.
Summary
Takeda will revise its FY2025 consolidated financial statements to include the $2.5 billion AMITIZA antitrust verdict, but expects no material impact on its FY2026 financial outlook.
Key Events · Legal and Risk Events · TAK
-
Financial Statement Revision Planned
Takeda will revise its FY2025 IFRS consolidated financial statements to account for the nearly $2.5 billion AMITIZA antitrust jury verdict.
-
FY2026 Guidance Unchanged
The company does not expect the verdict to materially impact its FY2026 financial forecast or management guidance, providing a degree of stability amidst the liability.
-
Follows Prior Verdict Disclosure
This accounting update follows the May 19, 2026 disclosure of the jury verdict in the AMITIZA antitrust litigation.
Analysis · TAK · Life Sciences
This filing details Takeda's plan to revise its FY2025 IFRS consolidated financial statements to reflect the nearly $2.5 billion jury verdict from the AMITIZA antitrust litigation. While the verdict itself was previously disclosed, this update clarifies the accounting treatment and, importantly, states that the company does not expect a material impact on its FY2026 financial forecast or management guidance. This provides some reassurance regarding the forward-looking financial health despite the significant liability.
How filings like this one have moved
In the 30 days to Oct 19, 2026, 37.9% of the 895 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.87%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, TAK was trading at $15.90 on NYSE in the Life Sciences sector, with a market capitalization of approximately $50.9B. The 52-week trading range was $12.99 to $18.90. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.